References
- Alloul K, Sauriol L, Kennedy W, Laurier C, Tessier G, Novosel S, Contandriopoulos A. Alzheimer's disease: A review of the disease, its epidemiology and economic impact. Gerontology and Geriatrics 1998; 27: 189–221
- Andreasen N, Blennow K. β-Amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease. Peptides 2002; 23: 1205–1214
- Band PR, Le ND, Fang R, Deschamps M. Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. The Lancet 2002; 360: 1044–1049
- Blennow K, Vanmechelen E. CSF markers for pathogenic processes in Alzheimer's disease: Diagnostic implications and use in clinical neurochemistry. Brain Research Bulletin 2003; 61: 235–242
- Box GEP, Behnken DW. Some new three level designs for the study of quantitative variables. Technometrics 1960; 2: 455–475
- Bridge MH, Williams E, Lyons MEG, Tipton KF, Linert W. Electrochemical investigation into the redox activity of Fe(II)/Fe(III) in the presence of nicotine and possible relations to neurodegenerative diseases. Biochimica et Biophysica Acta—Molecular Basis Diseases 2004; 1690: 77–84
- DeMarini DM. Genotoxicity of tobacco smoke and tobacco smoke condensate: A review. Mutation Research/Reviews in Mutation Research 2004; 567: 447–474
- Hernandez CM, Terry Jr AV. Repeated nicotine exposure in rats: Effects on memory function, cholinergic markers and nerve growth factor. Neuroscience 2005; 130: 997–1012
- Lemay S, Blanchet P, Chouinard S, Masson H, Soland V, Bedard MA. Poor tolerability of a transdermal nicotine treatment in Parkinson's disease. Clinical Neuropharmacology 2003; 26: 227–229
- Lemay S, Chouinard S, Blanchet P, Masson H, Soland V, Beuter A, Bedard MA. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Progress in Neuropsychopharmacology, Biology & Psychology 2004; 28: 31–39
- Liu P, Krishnan TR. Alginate–pectin–poly-L-lysine particulate as a potential controlled release formulation. Journal of Pharmaceutical Pharmacology 1999; 51: 141–149
- Newhouse PA, Kelton M. Nicotinic systems in central nervous systems disease: Degenerative disorders and beyond. Pharmaceutica Acta Helvetica 2000; 74: 91–101
- Newhouse PA, Potter A, Singh A. Effects of nicotinic stimulation on cognitive performance. Current Opinions in Pharmacology 2004; 4: 36–46
- Ono K, Hasegawa K, Yamada M, Naiki H. Nicotine breaks down preformed Alzheimer's β-amyloid fibrils in vitro. Biological Psychology 2002; 52: 880–886
- Pillay V, Danckwerts MP, Fassihi R. A crosslinked calcium-alginate-pectinate-cellulose acetophthalate gelisphere system for linear drug release. Drug Delivery 2002; 9: 77–86
- Pillay V, Fassihi R. In vitro release modulation from crosslinked pellets for site-specific drug delivery to the gastrointestinal tract. II. Physicochemical characterization of calcium-alginate, calcium-pectinate and calcium-alginate-pectinate pellets. Journal of Controlled Release 1999a; 59: 243–256
- Pillay V, Fassihi R. In vitro release modulation from crosslinked pellets for site-specific drug delivery to the gastrointestinal tract. I. Comparison of pH-responsive drug release and associated kinetics. Journal of Controlled Release 1999b; 59: 229–242
- Rusted JM, Newhouse PA, Levin ED. Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease. Behavioural Brain Research 2000; 113: 121–129
- Tammenmaa IA, Sailas E, McGrath JJ, Soares-Weiser K, Wahlbeck K. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: A meta-analysis of randomized controlled trials. Progress in Neuro-Psychpharmaceutical Biology & Psychology 2004; 28: 1099–1107
- Walkenström P, Kidman S, Hermansson AM, Rasmussen PB, Hoegh L. Microstructure and rheological behaviour of alginate/pectin mixed gels. Food Hydrocolloids 2003; 17: 593–603
- Williams E, Linert W. In vitro evidence supporting the therapeutic role of nicotine against neurodegeneration. In Vivo 2004; 1: 391–399